BME:PHMBiotechs
Assessing Pharma Mar (BME:PHM) Valuation After Zepzelca Milestones And EBITDA Surge
Pharma Mar (BME:PHM) drew investor attention after its 2025 earnings call, where management highlighted a 27% revenue increase and a fivefold rise in EBITDA, largely tied to Zepzelca related milestones.
See our latest analysis for Pharma Mar.
The 1 day share price return of 1.52% to €80.25 comes after a steady 90 day share price return of 6.64%. However, the 1 year total shareholder return of a 15.4% decline shows recent enthusiasm has not fully reversed earlier weakness.
If the Pharma Mar...